Stats from DataMonitor Healthcare suggest that preclinical oncology assets are highly sought after by Big Pharma. All amounts below are in US $.
In the period 2011-2015, approximately 32% of Big Pharma in-licensing involved oncology drugs, of which almost half were in the immuno-oncology field.
In the period 2011-2015, oncology also led Big Pharma in-licensing activity in terms of dollar value by therapeutic area, surpassing $51bn in headline value and including $4bn in up-fronts.
In the period 2011-2015, the majority of Big Pharma's oncology in-licensing deals (approximately 57%) were signed at preclinical to Phase I development stage.
In 2015, preclinical was the most popular stage for in-licensing activity by Big Pharma, accounting for 32% of deals.
In 2015, the average headline value for a Big Pharma in-licensing preclinical deal was ~$750m.
In 2015, the average upfront paid on in-licensing a preclinical asset was ~$100m.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)